A randomized, open, parallel controlled, multicenter phase II trial of apatinib mesylate for maintenance therapy of stage III-IV epithelial ovarian cancer after first-line treatment with complete or partial remission
Latest Information Update: 03 Oct 2019
At a glance
- Drugs Rivoceranib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
Most Recent Events
- 03 Oct 2019 New trial record